SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001867096-22-000111
Filing Date
2022-10-03
Accepted
2022-10-03 16:03:04
Documents
13
Period of Report
2022-09-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K xers-20220929.htm   iXBRL 8-K 40713
  Complete submission text file 0001867096-22-000111.txt   214846

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xers-20220929.xsd EX-101.SCH 2153
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xers-20220929_def.xml EX-101.DEF 15449
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xers-20220929_lab.xml EX-101.LAB 29866
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xers-20220929_pre.xml EX-101.PRE 16118
7 EXTRACTED XBRL INSTANCE DOCUMENT xers-20220929_htm.xml XML 11566
Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Filer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40880 | Film No.: 221287479
SIC: 2834 Pharmaceutical Preparations